Most hepatitis B carriers or hepatitis B patients learn that they are infected with the hepatitis B virus through medical examinations for school entry or employment. In addition to the fear of worsening their condition, hepatitis B discrimination is also the cause of their anxiety. In fact, hepatitis B is not highly contagious and will not be contracted by general contact. At present, many people in the society discriminate against hepatitis B carriers and hepatitis B patients because of prejudice, often manifested by refusing to shake hands with them, eat, share public facilities, etc. This seriously hurts the self-esteem of hepatitis B virus carriers and hepatitis B patients and interferes with their normal work, study and life. In fact, hepatitis B is not transmitted through the respiratory tract, digestive tract or contact, and daily contact does not infect you with the hepatitis B virus. The treatment of chronic hepatitis B includes antiviral, immunomodulatory, anti-inflammatory and hepatoprotective, anti-fibrotic and symptomatic treatment, of which antiviral treatment is the key. Long-term standardized antiviral therapy can effectively inhibit hepatitis B virus replication and slow down disease progression. However, not all patients with hepatitis B virus infection require antiviral therapy. Even with normal liver function, hepatitis B virus carriers may still have disease progression. The Chinese Guidelines for the Prevention and Treatment of Chronic Hepatitis B states that for chronic hepatitis B carriers, liver puncture should be performed and antiviral therapy is required if there are hepatitis lesions [≥G2 and/or ≥S2] on liver histology. If hepatitis lesions are not obvious or if the patient is unwilling to undergo liver aspiration, it is recommended to withhold treatment. Treatment is generally not required for inactive HBsAg carriers. Once the immune system and the hepatitis B virus are at war, liver function abnormalities and active hepatitis B virus replication arise, the hepatitis B virus carrier “turns into” a slow hepatitis B patient. This is when you need to go to a professional hospital to consult your doctor and undergo standardized antiviral treatment. In the premise that the hepatitis B virus cannot be completely “eliminated”, the most important “fortress” to overcome in hepatitis B treatment is to delay and stop disease progression, reduce and prevent liver decompensation, cirrhosis, hepatocellular carcinoma and its complications. Hepatocellular carcinoma and its complications. To achieve this “peace of mind”, we must adhere to long-term standardized antiviral therapy. Numerous clinical trials have demonstrated that standardized antiviral therapy can effectively suppress the hepatitis B virus, thereby delaying disease progression and reducing important clinical complications. As the hepatitis B virus can only be “suppressed” but not “eliminated”, hepatitis B treatment is limited to “treating the symptoms but not the root cause”. Blindly stopping the medication after short-term treatment (less than 1 year) will only lead to relapse and worsening of the disease. Therefore, antiviral treatment requires long-term adherence, at least 2-3 years, and is not a “battle” that can be won in one fell swoop in a short period of time. Therefore, when discussing drug selection, hepatitis B patients and doctors need to keep in mind that “long-term treatment” is a prerequisite and develop individualized treatment plans based on the principle of “three less” (less progression of cirrhosis and liver cancer, less adverse effects and less cost). In other words, to reduce and prevent the occurrence of cirrhosis, liver cancer and their complications; to consider the safety of long-term use of drugs, to choose drugs with fewer side effects; doctors must take into account the patient’s financial situation and ability to pay, and choose those drugs that patients can take regularly for at least 2-3 years.